New Findings from Capital Medical University Describe Advances in Acute Lymphoblastic Leukemia (A Study on Heterogeneity and Early Response to Chemotherapy in Pediatric ETV6-RUNX1 Positive Acute Lymphoblastic Leukemia By RNA-Seq Expression...).

A new report discusses research findings on acute lymphoblastic leukemia (ALL), specifically focusing on the heterogeneity and early response to chemotherapy in pediatric ETV6-RUNX1 positive ALL. The study conducted by Capital Medical University in Beijing, China, analyzed the RNA-seq expression profiles of 72 children with newly diagnosed ETV6-RUNX1 positive ALL. The research identified three distinct groups based on gene expression profiles and found that patients in the ER1 group may have a poorer early response to chemotherapy due to stronger proliferation and drug resistance of leukemic cells. The study suggests that patients in the ER1 group may require closer observation and consideration of escalated risk treatment, even if minimal residual disease is negative on the 15th day of chemotherapy. [Extracted from the article]

Copyright of Hematology Week is the property of NewsRx and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)